Furthermore, the report [12] found that loss of EphA5 resulted in higher expression of cancer stem cell (CSC) markers in HER2-positive breast cancer cells, including CD44+/CD24-/low, NANOG, CD133+. This evidence concerns the gene CD44 and breast cancer.